CVT-6883

DB05936ExperimentalSmall molecule

CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.

Mechanism: Pharmacologically active on Adenosine receptor A2b
Curator reviewed
Primary indication: Investigated for use/treatment in asthma.Curator reviewed
Formula / weight: C₂₁H₂₁F₃N₆O₂ · 446.434 g/mol (avg)
Code names: GS-6201

Resolves to

Compound

UNII67CKV7X08GCAS752222-83-6ChEMBLCHEMBL260933

Structure

InChIKeyKOYXXLLNCXWUNF-UHFFFAOYSA-NSMILESCCCN1C(=O)N(CC)C2=C(NC(=N2)C2=CN(CC3=CC=CC(=C3)C(F)(F)F)N=C2)C1=O

Targets

P29275ADORA2B

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with CVT-6883, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account